Publication | Open Access

A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study

Neurological DisorderNeurologyBrain LesionMultiple SclerosisMedicineNeuroimmunologyGadolinium-enhanced MriInspire Study